首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1383620

癌症生物治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、配銷通路、地區和競爭細分

Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Distribution Channel, By Region, and By Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022 年全球癌症生物治療市場價值為 963.3 億美元，預計到 2028 年預測期內將出現令人印象深刻的成長，複合CAGR為7.55%。全球癌症生物治療市場是指快速發展的癌症治療領域，該領域利用用於靶向和對抗癌細胞的生物製劑，例如單株抗體、細胞因子和疫苗。由於生物技術的進步和對癌症分子機制的不斷了解，多年來該市場見證了顯著的成長和創新。

主要市場促進因素

癌症發生率上升

市場概況
預測期	2024-2028
2022 年市場規模	963.3億美元
2028 年市場規模	1,485.9億美元
2023-2028 年CAGR	7.55%
成長最快的細分市場	單株抗體
最大的市場	北美洲

癌症長期以來一直是人類最強大的敵人之一，影響著全球數百萬人的生命。近年來，癌症發生率令人不安地激增，該疾病已成為日益嚴重的公共衛生問題。矛盾的是，這種不祥的趨勢也為癌症治療領域，特別是癌症生物治療領域的創新和進步創造了成熟的環境。

市場規模及預測
- 按價值
市佔率及預測
- 依產品（癌症生長阻斷劑、單株抗體、疫苗）
- 按配銷通路（醫院、零售和郵購藥局）
- 按國家/地區
MEA：國家分析
- 南非癌症生物治療
- 沙烏地阿拉伯癌症生物治療
- 阿拉伯聯合大公國癌症生物治療
- 科威特癌症生物治療

第 11 章：市場動態

促進要素
挑戰

第 12 章：市場趨勢與發展

近期發展
併購
產品發布

第 13 章：波特的五力分析

產業競爭
新進入者的潛力
供應商的力量
客戶的力量
替代產品的威脅

第14章：競爭格局

商業概覽
產品供應
最近的發展
財務（據報導）
主要人員
SWOT分析
- F Hoffmann-La Roche AG
- Novartis AG
- Merck & Co., Inc.
- Amgen Inc
- GSK PLC
- Celgene Corp
- Pfizer Inc
- Zydus Lifesciences Ltd
- Sun Pharmaceutical Industries Ltd
- Bayer AG

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄

Product Code: 18861

Global Cancer Biological Therapy Market has valued at USD 96.33 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.55% through 2028. The global cancer biological therapy market refers to the rapidly evolving field of cancer treatment that utilizes biological agents, such as monoclonal antibodies, cytokines, and vaccines, to target and combat cancer cells. This market has witnessed significant growth and innovation over the years due to advances in biotechnology and a growing understanding of the molecular mechanisms underlying cancer.

Key Market Drivers

Rising Cancer Incidence

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 96.33 Billion
Market Size 2028	USD 148.59 Billion
CAGR 2023-2028	7.55%
Fastest Growing Segment	Monoclonal Antibodies
Largest Market	North America

Cancer has long been one of humanity's most formidable adversaries, affecting millions of lives across the globe. Recent years have witnessed a troubling surge in cancer incidence rates, with the disease becoming an ever-increasing public health concern. Paradoxically, this ominous trend has also created an environment ripe for innovation and advancement in the field of cancer treatment, particularly in the realm of cancer biological therapies.

According to data from the World Health Organization (WHO), the incidence of cancer has been steadily climbing, with millions of new cases diagnosed each year. This upward trajectory is driven by a combination of factors, including an aging population, lifestyle changes, environmental factors, and improved cancer detection methods.

The escalating cancer burden has created a pressing need for more effective and targeted treatments. Conventional treatments like chemotherapy and radiation therapy, while valuable, often come with severe side effects and limited efficacy. Biological therapies, on the other hand, offer the promise of better outcomes with fewer side effects. The genetic diversity of cancer is well-documented, and this diversity often necessitates personalized treatment approaches. Biological therapies, such as targeted therapies, are designed to pinpoint specific molecular abnormalities or mutations in cancer cells. This precision allows for the development of tailored treatment plans, increasing their effectiveness. Immunotherapy, a subset of biological therapy, has made remarkable strides in recent years. These treatments harness the body's immune system to identify and attack cancer cells, offering the potential for long-lasting remissions and even cures. The increasing prevalence of immunotherapies like checkpoint inhibitors and CAR-T cell therapy is directly tied to their success in treating various cancer types. The pharmaceutical industry has responded to the rising cancer incidence by investing heavily in research and development. As the demand for more effective treatments grows, pharmaceutical companies are racing to develop and bring to market innovative cancer biological therapies, creating a competitive and dynamic landscape. Genetic testing and molecular profiling have become integral to cancer diagnosis and treatment planning. As the understanding of cancer genetics deepens, personalized medicine approaches are being employed to tailor cancer biological therapies to individual patients, optimizing treatment outcomes. The surge in cancer cases has prompted an increase in clinical trials for novel biological therapies. Regulatory agencies have also streamlined approval processes to expedite promising treatments to patients, further facilitating market growth. The global cancer biological therapy market is expanding beyond traditional markets, with emerging economies in Asia, Latin America, and the Middle East witnessing rapid growth. Improved healthcare infrastructure and increasing awareness of advanced cancer treatments are contributing to this expansion.

Advancements in Biotechnology

Biotechnology has emerged as a game-changer in the field of cancer treatment, revolutionizing the way we combat this complex and devastating disease. Advancements in biotechnology have led to the development of innovative and highly targeted cancer biological therapies that offer new hope for patients worldwide.

Biotechnology encompasses a broad spectrum of techniques and technologies that leverage biological systems, living organisms, or their derivatives to develop new products and processes. In the context of cancer treatment, biotechnology has become instrumental in understanding the underlying mechanisms of the disease, discovering novel therapeutic targets, and designing precision treatments.

Advances in biotechnology have deepened our understanding of the molecular and genetic basis of cancer. Researchers can now identify specific genetic mutations, biomarkers, and signaling pathways that drive tumor growth. This knowledge has paved the way for the development of targeted therapies, a cornerstone of cancer biological treatments.

Biotechnology has facilitated the production of monoclonal antibodies, which are engineered to bind to specific antigens on cancer cells. These antibodies can either block the growth signals of cancer cells or trigger the immune system to attack them. Monoclonal antibodies like trastuzumab (Herceptin) and rituximab (Rituxan) have revolutionized cancer treatment, particularly in breast and blood cancers.

Biotechnological advancements have enabled the development of cancer vaccines designed to stimulate the patient's immune system to recognize and attack cancer cells. Vaccines such as Provenge (sipuleucel-T) for prostate cancer and various therapeutic cancer vaccine candidates have shown promise in clinical trials.

Gene therapy, a cutting-edge biotechnological approach, involves modifying a patient's own genes to treat or prevent disease. In the context of cancer biological therapy, gene therapies are being developed to target and correct genetic mutations responsible for cancer. CAR-T cell therapies, which genetically engineer a patient's immune cells to fight cancer, exemplify this innovation.

Biotechnology has transformed drug discovery processes. High-throughput screening, computational biology, and bioinformatics tools enable researchers to identify potential drug candidates more efficiently. This has led to the discovery of novel molecules for cancer treatment.

Biotechnology has facilitated the discovery and validation of biomarkers, which are crucial for patient stratification and treatment response prediction. Biomarker-driven approaches help identify patients who are most likely to benefit from specific cancer biological therapies, making treatments more effective and personalized.

Biotechnology has improved bioprocessing and manufacturing techniques, ensuring the scalable production of biological therapies. This has lowered production costs and increased the availability of these treatments.

Immunotherapy Revolution

Immunotherapy, a groundbreaking approach to cancer treatment, has ignited a revolution in the field of oncology. This remarkable advancement harnesses the body's immune system to fight cancer cells, providing hope to patients and transforming the landscape of cancer care.

Immunotherapy represents a paradigm shift in cancer treatment. Unlike traditional therapies like chemotherapy and radiation, which directly target cancer cells, immunotherapy focuses on strengthening the body's own defenses against cancer. It stimulates the immune system to recognize and destroy cancer cells, offering several advantages.

Immunotherapy is highly precise. It targets only cancer cells while sparing healthy tissues, minimizing side effects. Some immunotherapies can induce durable responses, with the potential for sustained remission or even cures. Immunotherapy has expanded the arsenal of treatment options, particularly for advanced and hard-to-treat cancers.

Immunotherapy has demonstrated efficacy in various cancer types, including melanoma, lung, bladder, and kidney cancers, among others. As research continues, the potential applications of immunotherapy are expected to grow, widening its reach in the market. Checkpoint inhibitors are a class of immunotherapies that block proteins that inhibit the immune response, allowing the immune system to recognize and attack cancer cells. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have achieved remarkable success in clinical trials and have been approved for multiple indications, fueling market growth. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to express chimeric antigen receptors (CARs), which can recognize and target cancer cells. CAR-T therapies have shown exceptional results in treating certain blood cancers, such as leukemia and lymphoma. Researchers are exploring the potential of combining immunotherapies with other treatments, such as chemotherapy and targeted therapies. These combination approaches aim to enhance the effectiveness of cancer treatment and broaden the scope of immunotherapy applications. The ongoing research and development of immunotherapies through clinical trials are expanding the portfolio of available treatments. New immunotherapeutic agents and novel combinations are continuously being tested, driving innovation and market growth.

Targeted Therapies

Targeted therapies represent a transformative approach to cancer treatment, offering new hope to patients by directly targeting the molecular and genetic abnormalities that drive cancer growth. In recent years, these precise and innovative treatments have played a pivotal role in shaping the landscape of the global cancer biological therapy market.

Targeted therapies minimize harm to healthy tissues, reducing the often-debilitating side effects associated with traditional treatments. By directly addressing the underlying genetic or molecular drivers of cancer, targeted therapies can be more effective, especially in cancers where traditional treatments have limited impact. Targeted therapies are often tailored to individual patients based on genetic or molecular profiling, allowing for personalized treatment plans.

Advances in genomics and molecular biology have led to the discovery of numerous biomarkers and genetic mutations that drive cancer. Targeted therapies are developed to specifically address these aberrations, enabling more precise treatments. The pharmaceutical industry has invested heavily in research and development, leading to the creation of a wide range of targeted therapies. Drugs like imatinib (Gleevec), which targets the BCR-ABL gene in chronic myeloid leukemia (CML), have achieved remarkable success. Targeted therapies have demonstrated efficacy in various cancer types, including breast, lung, colorectal, and melanoma. As researchers uncover new targetable mutations, the scope of targeted therapy applications is expected to grow. Researchers are exploring the potential of combining targeted therapies with other treatments, such as immunotherapies and traditional chemotherapy. These combinations aim to enhance treatment effectiveness and broaden the range of treatable cancers. Ongoing clinical trials continue to expand the portfolio of available targeted therapies. New agents and innovative combinations are constantly being tested, driving innovation and market growth.

Key Market Challenges

High Costs and Accessibility

One of the most pressing challenges is the high cost associated with many cancers' biological therapies. These treatments can be expensive to develop, produce, and administer. Accessibility to these therapies becomes a critical issue, as not all patients can afford them, leading to disparities in care. Ensuring equitable access to these life-saving treatments remains a global challenge.

Resistance to Treatment

Over time, some cancer cells can develop resistance to targeted therapies, rendering them less effective. This phenomenon, known as treatment resistance, can limit the long-term success of these therapies. Researchers are actively working to understand and address resistance mechanisms, but it remains a significant challenge in the field.

Side Effects and Toxicities

While targeted therapies are often less toxic than traditional treatments like chemotherapy, they are not without side effects. Patients may experience adverse events, including skin reactions, gastrointestinal problems, and immune-related complications. Managing these side effects while maintaining treatment efficacy is a delicate balance.

Key Market Trends

Immunotherapy Combinations

Immunotherapy has revolutionized cancer treatment, and the trend toward combining different immunotherapies or immunotherapy with other treatment modalities is expected to gain traction. Researchers are exploring the synergy between checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines to enhance the effectiveness of immune-based therapies.

Biomarker-Driven Therapies

Precision medicine is increasingly guiding treatment decisions in oncology. The identification of novel biomarkers, including genetic mutations and molecular signatures, will continue to drive the development of highly targeted therapies. Biomarker-driven approaches ensure that patients receive the most appropriate treatment based on their unique tumor characteristics.

CAR-T Cell Therapy Expansion

CAR-T cell therapy, a form of immunotherapy that modifies a patient's T cells to target cancer cells, is gaining momentum. As research progresses, we can anticipate the approval of CAR-T therapies for additional cancer types beyond blood cancers, further broadening their applications.

Segmental Insights

Product Insights

Based on the category of Product, it is anticipated that the antibodies sector will assume a leading position in 2022. Antibodies are poised for substantial growth in the foreseeable future, primarily owing to their capacity to precisely target proteins on the cell surface. This precision makes them increasingly valuable in cancer therapy. Furthermore, the growing preference among patients for advanced biological therapies for cancer, which aim to mitigate the risks associated with traditional anti-cancer drug treatments, will fuel the expansion of this segment.

These laboratory-produced antibodies are designed to combat protein molecules expressed by malignant tumors. Examples of antibody medications in this category include rituximab, employed in the treatment of non-lymphoma; Hodgkin's alemtuzumab (Campath), utilized in the management of chronic leukemia (CLL); and ipilimumab (Yervoy), employed in the treatment of malignant melanoma. Moreover, the growing inclination towards advanced biological treatments for cancer, as a means to reduce the risks tied to conventional anti-cancer drugs, is poised to bring about significant growth within this segment. For instance, in the case of breast cancer, trastuzumab (Herceptin, Kanjinti, Ogivri) serves as an exemplar of a laboratory-developed antibody. It operates by impeding the proliferation of cancer cells through targeted adherence to specific regions on these cells.

Distribution Channel Insights

Retail and mail-order pharmacies are expected to command a substantial market share in the Global Cancer Biological Therapy Market during the forecast period for several compelling reasons. Firstly, the increasing prevalence of cancer worldwide necessitates easy access to advanced therapies, and retail and mail-order pharmacies provide a convenient distribution channel for these treatments. Moreover, as patients and healthcare providers increasingly opt for personalized cancer therapies, the ability of retail and mail-order pharmacies to offer a wide range of biological therapies tailored to individual patient needs positions them favorably in the market. Additionally, the global trend toward home-based healthcare services further accentuates the significance of these pharmacies, as they enable patients to access and receive cancer biological therapies in the comfort of their homes, promoting greater patient compliance and treatment effectiveness. As a result, the retail and mail-order pharmacy segment is poised to play a pivotal role in the growth and accessibility of cancer biological therapies during the forecast period.

Regional Insights

In the cancer biological therapy market from 2023 to 2032, North America takes the lead as the prominent region. The United States, in particular, emerges as the frontrunner both within North America and globally, attributed to a favorable reimbursement landscape coupled with substantial healthcare spending. Furthermore, the U.S. market benefits from an extensive network of cancer biological vaccine and drug manufacturers, bolstered by increased investments in research and development and government initiatives. Accessible health insurance policies covering life-threatening conditions incentivize individuals to seek these therapies, thereby driving market growth. The U.S. cancer gene therapy market has also witnessed significant expansion, thanks to a robust treatment pipeline and the increasing focus of industry players on pioneering cancer gene therapies and their delivery systems. An illustrative example of this trend is the extended collaboration agreement between the Cancer Institute, Inc. and McKesson Corporation announced on June 27, 2022.

In the second position for market profitability is Europe, owing to its high disposable income levels and widespread awareness. The region's substantial cancer burden, a significant elderly patient population, and advancements in cancer therapies further contribute to the potential for market growth in the upcoming years. Additionally, the introduction of novel molecular techniques, an evolving healthcare sector, and innovative technological approaches are expected to further augment the European market's prospects.

Key Market Players

F Hoffmann-La Roche AG

Novartis AG

Merck & Co., Inc.

Amgen Inc

GSK PLC

Celgene Corp

Pfizer Inc

Zydus Lifesciences Ltd

Sun Pharmaceutical Industries Ltd

Bayer AG

Report Scope:

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biological Therapy Market, By Product:

Cancer Growth Blockers
Monoclonal Antibodies
Vaccines

Cancer Biological Therapy Market, By Distribution Channel:

Hospitals
Retail & Mail Order Pharmacies

Cancer Biological Therapy Market, By Region:

North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customizations:

Global Cancer Biological Therapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biological Therapy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
- 5.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Product Market Map
- 5.3.1. By Product
- 5.3.2. By Distribution Channel
- 5.3.3. By Region

6. North America Cancer Biological Therapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
- 6.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Cancer Biological Therapy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Distribution Channel
- 6.3.2. Canada Cancer Biological Therapy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Distribution Channel
- 6.3.3. Mexico Cancer Biological Therapy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Distribution Channel

7. Europe Cancer Biological Therapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
- 7.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Cancer Biological Therapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Distribution Channel
- 7.3.2. United Kingdom Cancer Biological Therapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Distribution Channel
- 7.3.3. France Cancer Biological Therapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Cancer Biological Therapy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. Spain Cancer Biological Therapy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Cancer Biological Therapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
- 8.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Cancer Biological Therapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Distribution Channel
- 8.3.2. Japan Cancer Biological Therapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Distribution Channel
- 8.3.3. India Cancer Biological Therapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Distribution Channel
- 8.3.4. Australia Cancer Biological Therapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Distribution Channel
- 8.3.5. South Korea Cancer Biological Therapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Distribution Channel

9. South America Cancer Biological Therapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
- 9.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Cancer Biological Therapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Cancer Biological Therapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Cancer Biological Therapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Cancer Biological Therapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
- 10.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Cancer Biological Therapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Cancer Biological Therapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Cancer Biological Therapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Distribution Channel
- 10.3.4. Kuwait Cancer Biological Therapy Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Product
    - 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
- 14.6.1. F Hoffmann-La Roche AG
- 14.6.2. Novartis AG
- 14.6.3. Merck & Co., Inc.
- 14.6.4. Amgen Inc
- 14.6.5. GSK PLC
- 14.6.6. Celgene Corp
- 14.6.7. Pfizer Inc
- 14.6.8. Zydus Lifesciences Ltd
- 14.6.9. Sun Pharmaceutical Industries Ltd
- 14.6.10. Bayer AG